Innovative Medicine Backed by the Power of Artificial Intelligence

BioXcel Therapeutics, Inc. a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, to identify improved therapies in neuroscience and immuno-oncology.

About Us

Company’s Approach to Drug Development

Company’s Approach to Drug Development

AI-based Drug Development

Our neuroscience and immuno-oncology programs utilize our AI approach to drug development.


BXCL501 is an investigational, proprietary, orally dissolving, sublingual or buccal thin film formulation of dexmedetomidine designed for the treatment of agitation and substance abuse withdrawal symptoms.


BXCL701 is an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to check point inhibitors.

Sign up for Email Alerts

Email Sign Up

Stock Information

BioXcel Therapeutics, Inc.